Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Telavancin in Normal and Obese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult subjects, 18 to 50 years~* Nonsmokers within the last 1 year~* Weight \> 110 lbs~Exclusion Criteria:~* History of significant hypersensitivity reaction or intolerance to telavancin~* Aspartate or alanine aminotransferase \> 1.5 times the upper limit of normal~* Estimated creatinine clearance \<60 mL/minute and serum creatinine \>1.5 mg/dL~* Female subjects who are pregnant or breast feeding~* History of alcohol or substance abuse or dependence within the last 1 year~* Use of prescription or nonprescription drugs (unless hormonal contraceptives) within 7 to 14 days prior to telavancin administration~* Participation in a clinical trials within last 30 days~* Donated blood (\>500 mL) within the last 56 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Telavancin Administration (Type: EXPERIMENTAL): Single dose of telavancin administered as a 1-hour intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).